Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in ... MarketWatch (press release) "CMX001 in the Peri-Engraftment Period Does Not Impair Neutrophil Recovery in Pediatric Allogeneic Hematopoietic Stem Cell Recipients," will be presented by Michael S. Grimley, MD, Division of Bone Marrow Transplantation and Immune Deficiency, ... |
